Institutional shares held 33.5 Million
73.4K calls
12.6K puts
Total value of holdings $873M
$1.91M calls
$328K puts
Market Cap $1.28B
49,015,200 Shares Out.
Institutional ownership 68.34%
# of Institutions 262


Latest Institutional Activity in AMPH

Top Purchases

Q3 2025
Arrowstreet Capital, Limited Partnership Shares Held: 392K ($10.2M)
Q3 2025
Clark Capital Management Group, Inc. Shares Held: 284K ($7.39M)
Q3 2025
Algert Global LLC Shares Held: 393K ($10.2M)
Q3 2025
Ubs Group Ag Shares Held: 312K ($8.14M)
Q3 2025
Bridgeway Capital Management, LLC Shares Held: 312K ($8.14M)

Top Sells

Q3 2025
Pacer Advisors, Inc. Shares Held: 6K ($156K)
Q3 2025
Qube Research & Technologies LTD Shares Held: 241K ($6.29M)
Q3 2025
Cx Institutional Shares Held: 63.3K ($1.65M)
Q3 2025
Balyasny Asset Management LLC Shares Held: 142K ($3.7M)
Q3 2025
Goldman Sachs Group Inc Shares Held: 241K ($6.29M)

About AMPH

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.


Insider Transactions at AMPH

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.04M Shares
From 16 Insiders
Grant, award, or other acquisition 285K shares
Exercise of conversion of derivative security 755K shares
Sell / Disposition
523K Shares
From 10 Insiders
Open market or private sale 55.1K shares
Payment of exercise price or tax liability 468K shares
Bona fide gift 410 shares

Track Institutional and Insider Activities on AMPH

Follow Amphastar Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AMPH shares.

Notify only if

Insider Trading

Get notified when an Amphastar Pharmaceuticals, Inc. insider buys or sells AMPH shares.

Notify only if

News

Receive news related to Amphastar Pharmaceuticals, Inc.

Track Activities on AMPH